• Silo Pharma commended coordinated U.S. federal actions to fast-track psychedelic-based therapies for PTSD, citing an executive initiative to accelerate development.
• CEO Eric Weisblum said federal funding, clinical progress, and regulatory prioritization are laying groundwork for new PTSD treatments.
• Silo highlighted ARPA-H initial EVIDENT program awards as support for data-driven psychedelic research.
• Company pointed to FDA IND clearance for DemeRx NB noribogaine in alcohol use disorder as evidence of expanding clinical activity in mental health.
• Silo noted FDA issuance of three Commissioner’s National Priority Vouchers, citing imminent final guidance for psychedelic drug development.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Silo Pharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604290908PRIMZONEFULLFEED9709079) on April 29, 2026, and is solely responsible for the information contained therein.